Quantbot Technologies LP Has $1.72 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Quantbot Technologies LP lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 13.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,300 shares of the medical research company’s stock after acquiring an additional 1,131 shares during the quarter. Quantbot Technologies LP’s holdings in Charles River Laboratories International were worth $1,717,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Royal London Asset Management Ltd. grew its holdings in shares of Charles River Laboratories International by 6.4% during the fourth quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company’s stock worth $3,032,000 after purchasing an additional 991 shares during the last quarter. Cibc World Markets Corp boosted its position in Charles River Laboratories International by 16.1% during the 4th quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company’s stock worth $1,493,000 after buying an additional 1,124 shares during the period. Hilton Capital Management LLC grew its holdings in Charles River Laboratories International by 5.0% during the 4th quarter. Hilton Capital Management LLC now owns 8,038 shares of the medical research company’s stock worth $1,484,000 after acquiring an additional 380 shares during the last quarter. Impact Capital Partners LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at approximately $422,000. Finally, Truvestments Capital LLC raised its stake in shares of Charles River Laboratories International by 6.4% during the fourth quarter. Truvestments Capital LLC now owns 2,562 shares of the medical research company’s stock valued at $473,000 after acquiring an additional 155 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, CEO James C. Foster acquired 6,075 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 0.0 %

CRL opened at $167.29 on Tuesday. The company has a market cap of $8.55 billion, a P/E ratio of 1,115.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a fifty day moving average price of $165.66 and a two-hundred day moving average price of $183.49. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.57.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter last year, the firm posted $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of recent research reports. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price target for the company from $190.00 to $170.00 in a research note on Friday. Barclays lowered their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. Finally, UBS Group restated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).